Market by Mechanism, Indicator, Consumer, Commodity, and Regional Outlook | Forecast 2022-2028
A companion diagnostic, as defined by the Food and
Drug Administration (FDA), is a medical device, more frequently an
in-vitro diagnostic tool, that presents crucial data for the safe and efficient
use of a matching drug or therapy. A healthcare provider can use companion
diagnostic tests to assess whether a certain treatment product will give
patients more advantages than hazards. Moreover, it is personalized medicine
that encompasses drug testing, therapies, clinical trials, and research. It
increases the effectiveness of pharmaceuticals as therapeutic agents and lowers
the overall cost of healthcare during treatment.
According to Triton Market Research Analysis, the Global Companion Diagnostics Market was valued at $5314.48 million in 2021 and is expected to reach $12740.68 million by 2028, growing at a CAGR of 12.84% during the forecast period 2022-2028.
Click here to check out our blog on the Global Companion Diagnostics Market
MARKET PERFORMANCE: DRIVERS,
CHALLENGES, AND TRENDS
Over the forecast period, the market expansion
is likely to be fueled by increasing incidences of medication reactions,
surging cancer cases and fatalities, and the rising prevalence of precision
medicines. Precision
medicine, a patient-centered treatment strategy based on biomarker research,
holds promise in bringing a paradigm shift in the healthcare sector, making it
easier to eliminate the uncertainty associated with medication trial and error.
This ultimately eradicates needless healthcare spending. As a result, the
medical profession has been accepting precision medicine. The development of
cutting-edge technologies, including next-generation sequencing (NGS), liquid
biopsy, and companion diagnostics (CDx), has also been made possible by
advances in genomics, proteomics, molecular biology, data analytics, and
technical engineering.
The market, however, must overcome significant
obstacles like the weak reimbursement framework and common cases of leakage in
oncology companion diagnostics. To guarantee patient access to cutting-edge medical facilities and
support ongoing innovation in medical technologies, reimbursement coverage and
payment policies in public and private sectors are crucial. However, as
healthcare prices rise, legislators and insurance companies become less
supportive, reducing patient access to CDx testing and hindering companion
diagnostics R&D.
Nevertheless, the ongoing research and investments in next generation gene sequencing are expected to create varied opportunities for the market. NGS-based diagnostics, like the FoundationOne CDx from F Hoffmann-La Roche, aid in determining the most suitable course of treatment for each patient, thereby minimizing the use of trial-and-error methods in medicine. Several businesses are investing in creating tailored therapies, heavily impacting the expansion of the precision medicine sector. Besides, the Centers for Medicare & Medicaid Services (CMS) announced that beneficiaries with advanced cancer would receive coverage for companion diagnostics based on next-generation sequencing, removing the control of local contractors over coverage and enabling more uniform access to tests.
Report scope can be customized per your requirements. Request For Customization
KEY GEOGRAPHIES COVERED:
• North America: United
States and Canada
• Europe: United Kingdom,
France, Germany, Spain, Italy, Poland, and Rest of Europe
• Asia-Pacific: China,
Japan, India, South Korea, ASEAN Countries, Australia & New Zealand, and
Rest of Asia-Pacific
• Latin America: Brazil,
Mexico, and Rest of Latin America
• Middle East and Africa:
Saudi Arabia, Turkey, United Arab Emirates, South Africa, and Rest of Middle
East & Africa
SEGMENTATION ANALYSIS -
COMPANION DIAGNOSTICS MARKET:
• Market by Mechanism:
o In-Situ Hybridization
o Polymerase Chain Reaction
PCR
is one of the most popular tests in the companion diagnostics market, which had
a share of 38% in 2021.
Due to its effective use of biomarkers in treating leukemia, prostate, and
ovarian cancer, the PCR-based companion diagnostics market is anticipated to
maintain its dominant position. Additionally, PCR continues to be in demand
since it is used as a validation approach for NGS-based companion diagnostics.
o Immunohistochemistry
o Next Generation Sequencing
o Other
Mechanisms
• Market by Consumer:
o Pharmaceutical and
Biopharmaceutical Companies
o Reference Laboratories
o Other Consumers
• Market by Commodity:
o Assay Kits & Reagents
o Software & Services
• Market by Indicator:
o Oncology
The oncology industry extensively uses companion diagnostic tools to produce extremely precise treatments or
medications for specific cancer situations. An increase in cancer cases worldwide
is anticipated to hasten the use of companion diagnostics devices. In addition,
according to sources, Thermo Fisher Scientific and Cancer Genetics Inc worked
together in the latter's next-generation sequencing (NGS) companion diagnostics
center of excellence program to further research on cancer diagnostics.
o Neurology
o Infectious Disease
o Other Indicators
COMPETITIVE LANDSCAPE:
The companion diagnostics market by company profile helps dive into data
about the key players in this industry. The strategic initiatives for each of
the companies considered have been covered in detail.
Collaboration (November
2021): Arup Laboratories and PacBio
In November 2021, PacBio, a preeminent supplier of high-quality sequencing
technologies, and ARUP Laboratories declared their partnership to determine
whether it is possible to raise the solution rate for instances of rare
diseases.
Product Launch (February
2020) BioMerieux
In-vitro diagnostics' leading company, BioMerieux, introduced
MYACUTECASETM in February 2020. The first mobile application created by
BioMerieux interprets VIDAS emergency and critical care biomarker tests.
KEY BENEFITS OF THE REPORT:
●
Triton Market Research has a collective experience of 25-30 years
in the industry, with its analysts and experts encompassing the most infallible
research methodology for its market intelligence and industry analysis.
●
Our research methodology helps in achieving a broader consensus of
the market size, shape, and industry trends within each industry segment.
●
The strategy adopted in designing the research methodology
includes the amalgamation of the information assembled from primary and
secondary sources, with the assistance of analytical tools to construct the
forecast and predictive models.
●
The scope of the market report comprises the current scenario of
the global companion diagnostics market, along with the detailed overview of
the industry outlook, market dynamics, segmentation analysis, regional outlook,
and competitive landscape for the period 2022-2028.
FAQs:
Q 1) Does this report include
the impact of COVID-19 on the Companion Diagnostics market?
The market study has analyzed the impact of COVID-19 on the companion
diagnostics market qualitatively as well as quantitatively.
Q 2) Which type of mechanism
covered the major market share in 2021?
The majority of market share was held by polymerase chain reaction,
accounting for around 38% in 2021.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL
COMPANION DIAGNOSTICS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY
INSIGHTS
2.2.1. COMMERCIAL
SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION
OF PREDICTIVE BIOMARKERS
2.2.3. FUSION
OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. KEY
BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY
& SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. VENDOR
SCORECARD
2.7. INDUSTRY
COMPONENTS
2.8. REGULATORY
FRAMEWORK
2.9. KEY
MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT
LAUNCHES
2.9.3. CONTRACTS
& AGREEMENTS
2.10. MARKET
DRIVERS
2.10.1. INCREASE
IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING
PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING
PREVALENCE OF PRECISION MEDICINES
2.11. MARKET
CHALLENGES
2.11.1. WEAK
REIMBURSEMENT FRAMEWORK
2.11.2. COMMON
CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET
OPPORTUNITY
2.12.1. ONGOING
RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. GLOBAL
COMPANION DIAGNOSTICS MARKET OUTLOOK - BY MECHANISM
3.1. IN-SITU
HYBRIDIZATION
3.2. POLYMERASE
CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT
GENERATION SEQUENCING
3.5. OTHER
MECHANISMS
4. GLOBAL
COMPANION DIAGNOSTICS MARKET OUTLOOK - BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS
DISEASES
4.4. OTHER
INDICATORS
5. GLOBAL
COMPANION DIAGNOSTICS MARKET OUTLOOK - BY CONSUMER
5.1. PHARMACEUTICAL
AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE
LABORATORIES
5.3. OTHER
CONSUMERS
6. GLOBAL
COMPANION DIAGNOSTICS MARKET OUTLOOK - BY COMMODITY
6.1. ASSAY
KITS AND REAGENTS
6.2. SOFTWARE
AND SERVICES
7. GLOBAL
COMPANION DIAGNOSTICS MARKET - REGIONAL OUTLOOK
7.1. NORTH AMERICA
7.1.1. MARKET
OUTLOOK BY MECHANISM
7.1.2. MARKET
OUTLOOK BY INDICATOR
7.1.3. MARKET
OUTLOOK BY CONSUMER
7.1.4. MARKET
OUTLOOK BY COMMODITY
7.1.5. COUNTRY
ANALYSIS
7.1.5.1. UNITED
STATES
7.1.5.2. CANADA
7.2. EUROPE
7.2.1. MARKET
OUTLOOK BY MECHANISM
7.2.2. MARKET
OUTLOOK BY INDICATOR
7.2.3. MARKET
OUTLOOK BY CONSUMER
7.2.4. MARKET
OUTLOOK BY COMMODITY
7.2.5. COUNTRY
ANALYSIS
7.2.5.1. UNITED
KINGDOM
7.2.5.2. GERMANY
7.2.5.3. FRANCE
7.2.5.4. SPAIN
7.2.5.5. ITALY
7.2.5.6. POLAND
7.2.5.7. REST
OF EUROPE
7.3. ASIA-PACIFIC
7.3.1. MARKET
OUTLOOK BY MECHANISM
7.3.2. MARKET
OUTLOOK BY INDICATOR
7.3.3. MARKET
OUTLOOK BY CONSUMER
7.3.4. MARKET
OUTLOOK BY COMMODITY
7.3.5. COUNTRY
ANALYSIS
7.3.5.1. CHINA
7.3.5.2. JAPAN
7.3.5.3. INDIA
7.3.5.4. SOUTH
KOREA
7.3.5.5. ASEAN
COUNTRIES
7.3.5.6. AUSTRALIA
& NEW ZEALAND
7.3.5.7. REST
OF ASIA-PACIFIC
7.4. LATIN
AMERICA
7.4.1. MARKET
OUTLOOK BY MECHANISM
7.4.2. MARKET
OUTLOOK BY INDICATOR
7.4.3. MARKET
OUTLOOK BY CONSUMER
7.4.4. MARKET
OUTLOOK BY COMMODITY
7.4.5. COUNTRY
ANALYSIS
7.4.5.1. BRAZIL
7.4.5.2. MEXICO
7.4.5.3. REST
OF LATIN AMERICA
7.5. MIDDLE
EAST AND AFRICA
7.5.1. MARKET
OUTLOOK BY MECHANISM
7.5.2. MARKET
OUTLOOK BY INDICATOR
7.5.3. MARKET
OUTLOOK BY CONSUMER
7.5.4. MARKET
OUTLOOK BY COMMODITY
7.5.5. COUNTRY
ANALYSIS
7.5.5.1. UNITED
ARAB EMIRATES
7.5.5.2. SAUDI
ARABIA
7.5.5.3. TURKEY
7.5.5.4. SOUTH
AFRICA
7.5.5.5. REST
OF MIDDLE EAST & AFRICA
8. COMPETITIVE
LANDSCAPE
8.1. ABBOTT
LABORATORIES
8.2. ALMAC
GROUP
8.3. ARUP
LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER
CORPORATION
8.7. GE
HEALTHCARE
8.8. GENOMIC
HEALTH
8.9. ILLUMINA
INC
8.10. MYRIAD
GENETICS
8.11. QIAGEN
8.12. ROCHE
DIAGNOSTICS
8.13. SYSMEX
CORPORATION
8.14. THERMO
FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH
METHODOLOGY & SCOPE
9.1. RESEARCH
SCOPE & DELIVERABLES
9.2. SOURCES
OF DATA
9.3. RESEARCH
METHODOLOGY
TABLE 1: GLOBAL COMPANION
DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT LAUNCHES
TABLE 5: LIST OF CONTRACTS
& AGREEMENTS
TABLE 6: NUMBER OF CANCER
PATIENTS IN 2020
TABLE 7: GLOBAL COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: GLOBAL COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: GLOBAL COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: GLOBAL COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: GLOBAL COMPANION
DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 15: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 16: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 17: EUROPE COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 18: EUROPE COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 19: EUROPE COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 20: EUROPE COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 21: EUROPE COMPANION
DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 23: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 24: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 25: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 26: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 27: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 28: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 29: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 30: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 31: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 32: MIDDLE EAST AND
AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $
MILLION)
TABLE 33: MIDDLE EAST AND
AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $
MILLION)
TABLE 34: MIDDLE EAST AND
AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $
MILLION)
TABLE 35: MIDDLE EAST AND
AFRICA COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $
MILLION)
TABLE 36: MIDDLE EAST AND
AFRICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: GLOBAL COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $ MILLION)
FIGURE 8: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $ MILLION)
FIGURE 10: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: GLOBAL COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: GLOBAL COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES,
2022-2028 (IN $ MILLION)
FIGURE 18: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $ MILLION)
FIGURE 19: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: GLOBAL COMPANION
DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $ MILLION)
FIGURE 22: GLOBAL COMPANION
DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $ MILLION)
FIGURE 23: GLOBAL COMPANION
DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 25: UNITED STATES
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 26: CANADA COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 27: EUROPE COMPANION
DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 28: UNITED KINGDOM
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 29: GERMANY COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 30: FRANCE COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 31: SPAIN COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: ITALY COMPANION DIAGNOSTICS
MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: POLAND COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 34: REST OF EUROPE
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 35: ASIA-PACIFIC
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 36: CHINA COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 37: JAPAN COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 38: INDIA COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 39: SOUTH KOREA COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 40: ASEAN COUNTRIES
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 41: AUSTRALIA & NEW
ZEALAND COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 42: REST OF
ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 43: LATIN AMERICA
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021
FIGURE 44: BRAZIL COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 45: MEXICO COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 46: REST OF LATIN
AMERICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 47: MIDDLE EAST &
AFRICA COMPANION DIAGNOSTICS MARKET COUNTRY OUTLOOK, 2021
FIGURE 48: UNITED ARAB
EMIRATES COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 49: SAUDI ARABIA
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 50: TURKEY COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 51: SOUTH AFRICA
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 52: REST OF MIDDLE EAST
& AFRICA COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)